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Abstract
Background: Proteomic profiling of extracellular vesicles (EVs) from prostate cancer
(PCa) and normal prostate cell lines, led to the identification of new candidate PCa
markers. These proteins included the nuclear exportin proteins XPO1 (also known as
CRM1), the EV‐associated PDCD6IP (also known as ALIX), and the previously
published fatty acid synthase FASN. In this study, we investigated differences in
expression of XPO1 and PDCD6IP on well‐characterized prostate cancer cohorts
using mass spectrometry and tissue microarray (TMA) immunohistochemistry to
determine their diagnostic and prognostic value.
Methods: Protein fractions from 67 tissue samples (n = 33 normal adjacent prostate
[NAP] and n = 34 PCa) were analyzed by mass spectrometry (nano‐LC‐MS‐MS). Label‐free
quantification of EVs was performed to identify differentially expressed proteins between
PCa and NAP. Prognostic evaluation of the candidate markers was performed with a TMA,
containing 481 radical prostatectomy samples. Samples were stained for the candidate
markers and correlated with patient information and clinicopathological outcome.
Results: XPO1 was higher expressed in PCa compared to NAP in the MS data analysis
(P > 0.0001). PDCD6IP was not significantly higher expressed (P = 0.0501). High
cytoplasmic XPO1 staining in the TMA immunohistochemistry, correlated in a multi-
variable model with high Gleason scores (P = 0.002) and PCa‐related death (P = 0.009).
Conclusion: High expression of cytoplasmic XPO1 shows correlation with prostate
cancer and has added clinical value in tissue samples. Furthermore, as an extracellular
vesicles‐associated protein, it might be a novel relevant liquid biomarker.
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1 | INTRODUCTION
Biomarker discovery via extracellular vesicles (EVs; often referred to
as exosomes) released by (cancer) cells, has been the focus of many
research groups in the last decade.1,2 Based on their biogenesis and
secretion pathway, they contain low‐abundant, cancer‐specific
proteins, and RNAs that could be of interest in identifying novel
biomarkers.3 With respect to prostate cancer (PCa), several
EV‐derived candidate biomarkers have been revealed.4–10
Although multiple markers have been proposed as candidates for
several malignancies, the majority has been identified and validated
in EVs derived from cell culture. Few of the candidate biomarkers
have been validated on larger groups of patient samples. Because this
validation step is rarely taken, it remains difficult to elucidate the full
potential of EV markers, which limits its translation and clinical
implementation.11,12
Our own efforts, by using state‐of‐the‐art mass spectrometry, has
led to the discovery of some candidate markers of which XPO1 (also
known as CRM1), FASN, and PDCD6IP (also known as ALIX) were
found to have the highest potential.7 The objective of this study was
to investigate whether the PCa EV‐associated expression could be
reproduced in tissue analyses of larger cohorts of patients. Result for
FASN has been published previously.13
2 | MATERIALS AND METHODS
2.1 | Mass spectrometry
Protein fractions from tissue RNA isolations with RNA‐Bee of 67 PCa
tissue samples (33 NAP and 34 PCa) were selected and stored at
−80°C as described in Rodriguez et al.13 Samples were thawed and
50 µL precipitated with cold acetone and microcentrifugation. After
10 minutes, the supernatant was removed and the pellet washed
twice with cold acetone. The supernatant was removed and 50 µL of
0.1% RapiGest (Waters Corporation, Milford, MA) in 50 mM
NH4HCO3 was added to the protein pellet. The protein pellet was
dissolved by external sonification for 5 minutes at 70% amplitude at
room temperature (Digital Sonifier model 450, Branson, Danbury,
CT). The proteins were reduced with 10 mM dithiothreitol at 60°C
for 30 minutes. After cooling down to room temperature, it was
alkylated with 50 mM iodoacetamide for 30 minutes, and digested
overnight with 8 µL trypsin (Promega, Madison, WI). Subsequently,
6 µL of 5% TFA was added to inactivate digestion and incubated for
30 minutes at 37°C. Samples were centrifuged at maximum speed for
60 minutes at 4°C and the supernatant was transferred to new tubes.
A total of 5 µL was diluted 40 times and subsequently transferred to
LC vials for LC‐MS analysis. Upon analysis, 2 µL was injected to the
nano‐LC. After preconcentration and washing of the sample it was
loaded on to a C18 column (PepMap C18, 75 mm ID × 500 mm, 2 μm
particle, and 100 Å pore size; Thermo Fisher Scientific, Bremen,
Germany) using a linear 90 minutes gradient (4%‐25% acetonitrile/
H20; 0.1% formic acid) at a flow rate of 250 nL/minute. The
separation of the peptides was monitored by a UV detector
(absorption at 214 nm). The nano‐LC was coupled to a nanospray
source of a Q‐Exactive plus mass spectrometer (Thermo Fisher
Scientific, Bremen, Germany). Full scan MS spectra (m/z 400‐1600) in
profile mode were acquired in the Orbitrap with a resolution of 70
000 after the accumulation of an AGC target of 1 × 106. The top 12
peptide signals (charge‐state 2+ and higher) were isolated (1.6 Da
window) and fragmented by HCD (higher‐energy collision, normal-
ized collision energy 28.0) and measured in the Orbitrap with an AGC
target of 50 000 and a resolution of 17 500. Maximum fill times were
100 ms for the full scans and 60 ms for the MS/MS scans. The
dynamic exclusion was activated, after the first time a precursor was
selected for fragmentation it was excluded for a period of 30 seconds
using a relative mass window of 10 ppm. Lock mass correction was
activated to improve mass accuracy of the survey scan.
Label‐free quantitation was performed using Progenesis
LC‐MS Software (version 3.0; Nonlinear Dynamics Ltd., New-
castle‐upon‐Tyne, UK) following our previously reported metho-
dology.14,15 To get quantitative data, we selected only proteins
identified by three or more peptides for statistical analysis of
protein abundance between groups. Duplicates in identified
sequences as a consequence of peak tailing were removed to
avoid false positives. Technical replicates of each sample were
randomly analyzed within the measurement period and no
significant changes in the number of identified proteins were
observed between replicates and quality control measurements.
2.2 | Tissue microarray
A tissue microarray (TMA) was constructed as published pre-
viously.16 Briefly, 481 men were selected from the European
Randomized Study of Screening for prostate cancer (ERSPC), who
had undergone radical prostatectomy for PCa.17 From each patient
sample, three representative cores (diameter 0.6 mm) were taken
and placed in nine paraffin blocks. Patient information and clinical
follow data were recorded via the ERSPC protocol and stored in a
central study database.
For immunohistochemical (IHC) staining the tissues slides were
mounted on aminoacetylsilane coated glass slides (Starfrost, Berlin,
Germany), deparaffinized with xylene and dehydrated in ethanol. The
slides were placed in 0.3% hydrogen peroxide in PBS for 20 minutes
to block endogenous peroxidase activity. Microwave pretreatment
was performed for 15 minutes in tris (hydroxymethyl)aminomethane‐
ethylenediaminetetraacetic acid (pH 9.0). Subsequently, the slides
were incubated with PDCD6IP (1:400), FASN (1:50), and XPO1
(1:50) antibodies, overnight at 4°C. The EnVision DAKO kit (DAKO,
Glostrup, Denmark) was used for chromogenic visualization. Coun-
terstaining was performed with hematoxylin, which was followed by
dehydration and mounting in malinol (Chroma‐Geselschaft, Körgen,
Germany).
Staining intensities of each antibody were scored indepen-
dently by two investigators (DD, AMH) as negative (0; no staining),
weak (1; only visible at high magnification), moderate (2; visible at
low magnification), and strong (3; striking at low magnification).18
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Based on previous IHC staining results, for XPO1 a score was
assigned to both nuclear staining and cytoplasmic staining.7 For
PDCD6IP only the cytoplasmic expression was scored. In cases of
staining heterogeneity, the highest expression levels were used for
statistical analysis. After scoring, the average intensity for the
triplicate cores was calculated. When a core was missing or no
cancer was observed, this respective case was excluded from the
analysis. In a combined session consensus on expression value was
reached in all cases.
Statistical association of staining intensities and clinic‐pathologi-
cal features (PSA at diagnosis, Gleason score (GS), pT‐stage, surgical
margins, biochemical recurrence, local recurrence, overall death, and
PCa‐related death) were performed with SPSS (version 17, SPSS Inc.,
Chicago, IL) by using Pearsonʼs χ2 tests and Studentʼs t tests. A
multivariable analysis was performed to determine the contribution
of each individual variable. A P‐ < 0.05 was considered to be
statistically significant.
3 | RESULTS
3.1 | Protein expression by mass spectrometry
We previously published a list with proteins (n = 263) that were identified
in EVs from normal prostate (PNT2C2 and RWPE‐1) and PCa (VCaP
and PC346c) cell lines by using mass spectrometry.7 From this list,
10 proteins were identified as higher expressed in PCa‐derived EVs of
which expression of 3 proteins (XPO1, FASN, and PDCD6IP) were
further analyzed for EV and tissue expression. For a first validation, we
compared the 263 proteins to a shotgun mass spectrometry database
recently published which 34 PCa (n = 22 GS 6, n = 12 GS≥ 7) and 33 NAP
tissues were compared using label‐free quantification.19 In this database,
a total of 2865 proteins were identified from which 798 proteins were
statistically significant differentially expressed between normal prostate
and PCa (FDR < 0.01). When compared to the list of EV‐derived proteins,
42 of these proteins showed overlap (Figure 1A and Table 1).
F IGURE 1 A, Overlap of proteins
between the discovery set of extracellular
vesicle‐associated proteins (n = 263)7 and
the proteins differentially expressed
between prostate cancer (PCa) and normal
adjacent prostate (NAP) tissue (n = 798).13
B, Protein expression (LOG10 normalized)
of XPO1 and PDCD6IP in NAP (n = 33) and
PCa tissue (n = 34) and in C, Gleason score
< 7 (n = 22) vs Gleason score ≥ 7 (n = 12)
[Color figure can be viewed at
wileyonlinelibrary.com]
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Our previously identified candidate PCa‐EV biomarkers XPO1
(P < 0.0001) and FASN (P < 0.0001) were higher expressed in PCa
tissue, while PDCD6IP was borderline not significantly higher
expressed (P = 0.0501) (Table 1; Figure 1B). Interestingly, poly-
adenylate‐binding protein 1 (PABCP1) was higher expressed in
PCa‐derived EVs but showed significantly lower expression in PCaT
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TABLE 2 Patient characteristics and clinicopathological para-
meters of the prostate samples after treatment by radical prosta-
tectomy (n = 481) as was published by Hoogland et al16
Patient characteristics and
clinico‐pathological
parameters
Total number of
patients (%)
Mean
(variation)
Age at diagnosis, y 64.5 (55‐75)
>60 n = 411 (85.4)
>65 n = 260 (54.0)
>70 n = 57 (10.6)
Follow‐up, mo 113.3 (0‐204)
PSA levels at diagnosis, ng/mL 7.2 (0.3‐125)
>2.5 n = 440 (91.5)
>4 n = 333 (69.2)
>10 n = 62 (12.9)
Gleason sum
<7 n = 199 (41.4)
=7 n = 188 (39.1)
>7 n = 28 (5.8)
Pathological T‐stage (TNM 2002)
T2a n = 84 (17.5)
T2b n = 10 (2.1)
T2c n = 246 (51.1)
T3a n = 93 (19.3)
T3b n = 17 (3.5)
T4 n = 28 (5.8)
Surgical margins
Positive n = 119 (24.7)
Negative n = 362 (75.3)
Biochemical recurrence, mo 40.9 (0‐205)
Yes n = 119 (24.7)
No n = 362 (75.3)
Local recurrence, mo 110.0 (6‐146)
Yes n = 24 (5.0)
No n = 457 (95.0)
Overall death, mo 113.7 (0‐202)
Yes n = 112 (23.3)
No n = 368 (76.6)
Prostate cancer related death
Yes n = 12 (10.7)
No n = 74 (66.0)
Unknown n = 26 (23.2)
Abbreviation: PSA, prostrate specific antigen.
DUIJVESZ ET AL. | 1037
tissue when compared to NAP (P = 0.0015). Four other proteins
(CD9, EEF1A2, UBA52, and BCAM) were not significantly differen-
tially expressed in the tissue proteomics. The PCa‐derived EV
proteins VPS28 and ACTR3B were not identified in the tissue
validation set. Proteins that were higher expressed in normal
prostate cell line EVs were also cross‐validated on MS‐MS data of
tissue samples and are shown in Table 1. Although 15 of the 34 were
differentially expressed in both datasets, only 4 of the 15 showed the
same direction of higher expressed in EVs from immortalized normal
prostate epithelial cell lines and higher expressed in NAP tissue.
When expression of proteins was compared, XPO1 was sig-
nificantly higher expressed in PCa (Figure 1B), but no difference
(P = 0.696) was observed between low risk (GS 6) and intermediate/
high‐risk PCa (GS ≥ 7) (Figure 1C). Interestingly, PDCD6IP was
significantly lower expressed in intermediate/high risk in prostate
tissue (P = 0.017) (Figure 1C).
3.2 | Protein expression by tissue microarray
immunohistochemistry
For independent validation of XPO1 and PDCD6IP, immunohisto-
chemistry (IHC) was performed on the TMA. Patient characteristics
and clinicopathological parameters are shown in Table 2 and were
previously published by Hoogland et al.16 Briefly, the mean age at the
time of radical prostatectomy was 64.7 years; follow‐up was 113.3
months. Gleason score after radical prostatectomy was <7 in 265
(55.1%), 7 in 188 (39.1%), and >7 in 28 (5.8%) patients. Surgical
margins were negative in 362 (75.3%) patients. Biochemical
recurrence was observed in 119 (24.7%) patients after an average
of 40.9 months. Staining intensities of the candidate biomarkers
could not be assessed in 57 of the 481 samples (11.8%) because the
tumor was absent.
Antibody IHC verification and impression of the tissue staining of
the three candidate protein markers was published previously and
further expanded as depicted in Figure 2.7 XPO1, PDCD6IP, and
FASN stainings were observed in all samples, mainly in epithelial
cells. We noticed that the XPO1 expression varied within and
between the nuclear and cytoplasmic compartments. Nuclear XPO1
expression was present in 98.4% of cases and cytoplasmic expression
was observed in 74.5% of cases. XPO1 showed strong nuclear and
low cytoplasmic expression in luminal cells in NAP.7 With the
progression of PCa and increasing GS, cytoplasmic XPO1 expression
increased (Figure 2). PDCD6IP showed high expression in both
luminal and basal cells in NAP.
Subsequently, we evaluated the association between protein
expression intensities of our three candidate biomarkers and PSA
at diagnosis, GS, pT‐stage, surgical margins, biochemical recur-
rence, local recurrence, overall death and PCa‐related death
(Tables 3,4; Table S1). Nuclear XPO1 expression and PDCD6IP
did not correlate with any clinicopathological parameter. High
cytoplasmic XPO1 expression correlated with GS ≥ 7 (P = 0.002)
and PCa‐specific death after multivariate analysis (P = 0.009)
(Table 4). All other parameters were not significantly different.
The FASN TMA analyses have recently been published as part of
the tissue proteomics study and revealed that expression among
the PCa samples was higher in GS < 7 and GS = 7 (49.0% and
34.6%, respectively) than in GS > 7 (5.4%). This is in agreement
with previous studies.6,19
F IGURE 2 Immunohistochemical staining of XPO1, FASN, and PDCD6IP on normal adjacent prostate (NAP) and prostate cancer (PCa) with
increasing Gleason scores (GS). Picture was partially published before.7 [Color figure can be viewed at wileyonlinelibrary.com]
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4 | DISCUSSION
In this study we investigated whether previously identified PCa EV‐
derived proteins were differentially expressed in PCa tissue from
patients using mass spectrometry and immunohistochemistry. We
found that XPO1 was associated with PCa in mass spectrometry and
with higher GS using IHC on our TMA. PDCD6IP was not associated
with adverse clinicopathological characteristics.
XPO1 (also known as CRM1) mediates nuclear export of proteins
and RNAs and its differential expression has been linked to multiple
types of cancer.20–22 These transported proteins play a role in tumor
signaling pathways, including the AR‐pathway.23,24 XPO1 has already
been identified as a marker for several malignancies.21 We identified
this protein to be higher expressed in EVs derived from the VCaP PCa
TABLE 3 Scored staining intensity and distribution of the
cytoplasmic and nuclear XPO1 in our tissue microarray
Expression nuclear XPO1 0 1 2 3 Total P‐value
PSA at diagnosis
≤10 ng/mL 5 66 217 119 396 0.012
>10 ng/mL 1 16 35 8 60
Total 6 71 252 127 456
Gleason score
<7 5 40 129 74 248 0.145
7 0 26 105 50 181
>7 1 5 19 3 28
Total 6 71 253 127 457
pT‐stage
pT2 5 49 177 93 324 0.345
pT3a/b 1 14 65 26 106
pT4 0 8 11 8 27
Total 6 71 253 127 457
PSA at diagnosis
≤10 ng/mL 104 236 55 1 396 0.920
>10 ng/mL 15 38 7 0 60
Total 119 274 62 1 456
Gleason score
<7 79 146 23 0 248 0.002
7 40 109 31 1 181
>7 1 19 8 0 28
Total 120 274 62 1 457
pT‐stage
pT2 92 195 36 1 324 0.221
pT3a/b 23 61 22 0 106
pT4 5 18 4 0 27
Total 120 274 62 1 457
Intensity was scored as negative (0; no staining), weak (1; only visible at
high magnification), moderate (2; visible at low magnification), or strong
(3; striking at low magnification). Staining intensities were correlated with
patient characteristics after radical prostatectomy
Abbreviation: PSA, prostrate specific antigen.
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cell line.7 In this current study, we observed higher expression in PCa
tissue as compared to NAP, which could explain the increased EV
expression. From the TMA, we noticed that when GS increased, nuclear
staining decreased and cytoplasmic XPO1 location increased. This
provides us with an additional explanation for the increased presence of
this 123 kDa nuclear export protein in EVs: a shift towards cytoplasmic
expression could increase the random chance or even active escorting
of XPO1 into extracellular vesicles.
When correlated to clinicopathological parameters, we observed
a significant correlation between higher XPO1 cytoplasmic expres-
sion with higher GS (7 or higher) and disease‐specific death.
Therefore, this finding implies that there seems to be a clinical role
as a tissue marker regarding prognosis for PCa. The correlation with
disease‐specific death could only be addressed in 12 patients.
Because of the limited number of patients with PCa‐related death,
we should be careful to draw conclusions regarding the correlation of
cytoplasmic XPO1 and this clinical parameter.
Interestingly, recent reports have been published on the
functional role of XPO1 and the effect of cancer by inhibition of
XPO1‐mediated transport. Administration of selective inhibitors of
nuclear transport (SINE) such as Selinexor, have led to an enrichment
of tumor suppressor proteins in the nucleus.25 This subsequently
resulted in apoptosis, reduction of tumor spreading and improved
overall survival in preclinical models in PCa.26–28 Clinical studies are
being performed to reveal the real potential of XPO1‐directed
therapy.
FASN has already been described as a potential marker for
PCa.29,30 A recent study by Hamada et al31, showed that expression
of this protein on biopsies could be a marker for the upgrading of GS
after radical prostatectomy. Furthermore, Wu et al32 showed that
this protein is useful for the diagnosis of PCa. However, both studies
were performed on relatively small groups (<100 patient samples).
Although we previously showed higher expression of FASN in PCa
EVs, Rodriguez‐Blanco et al19, could only observe a statistically
significant difference with normal prostate tissue in our TMA. When
expression was compared with clinicopathological parameters, no
statistically significant difference was observed. So far, FASN could
be used as a marker for the diagnosis PCa, but the expression in
normal cells is also relatively high. This makes it difficult for
distinguishing between disease and healthy tissue.
PDCD6IP has scarcely been reported as a tumor marker or as
having a role in tumor biology. PDCD6IP (also referred to as ALIX) is
involved in endocytosis, multivesicular body biogenesis, apoptosis,
membrane repair, and directly related to EV formation.33,34 Although
PDCD6IP is used as a general marker for EVs, the transformation of
healthy cells to cancerous cells could interfere with EV formation and
therefore the presence of PDCD6IP could be altered. Our current
study showed no statistical difference of expression between NAP
and PCa tissue, nor did we find decreased PDCD6IP expression in
patients with GS≥7 in our TMA. Furthermore, PDCD6IP did not
correlate to any clinicopathological parameters. We conclude that
over‐representation of PDCD6IP in EVs from VCaP and PC346c is
not explained by a general higher expression of this protein in PCa.
Although PDCD6IP differential expression in EVs could not be
validated with tissue MS‐MS and TMA IHC, it would be interesting to
see whether this marker still shows clinical potential when an easily
applicable EV‐specific assay (such as an ELISA) is applied.
From our mass spectrometry and TMA analyses, we have learned
that overexpression and cytoplasmic compartmentalization provides
an explanation for the increased presence of XPO1 in PCa‐derived
EVs. The absence of a correlation between tissue and EV expression
for PCDC6IP suggest that also other mechanisms play a role in
EV‐mediated secretion. The most obvious would be specific escorting
of proteins in extracellular vesicles via the ESCRT system.35,36
Whether this pathway is changed in cancer development and
progression is not fully known.37
Besides XPO1, FASN, and PDCD6IP, our analyses also provided
more data for new candidate EV biomarkers: The 16 additional
proteins that were identified in EVs and also differentially expressed
in the tissue MS analyses. It is worthwhile to investigate whether
these PCa tissue‐dysregulated, EV‐detectable proteins are EV
biomarkers in other cell lines and in clinical samples. From this list,
PABPC1, CLIC1, RAB10, and PKM2 have been identified as a
potential marker for (prostate) cancer. 38–41 High expression of
ANXA2 has been shown to have an unfavorable prognosis in multiple
malignancies.42 Within this group of potential biomarkers, it is of
interest to note that the level of expression in EVs from normal
versus PCa cell lines is not always in the same direction as the NAP
versus PCa tissue MS (Table 1). Besides the comparison of a few 2D
grown cell lines with patient tissue samples, changes in cytoplasmic
subcellular location and specific EV sorting of proteins can explain
such apparent discrepancies.
XPO1, FASN, and PCDC6IP are known or expected to be intra‐
vesicular proteins and a detection assay to determine their levels in
EVs from bodyfluids will likely involve multiple steps: EV isolation
and disruption followed by protein measurement using enzyme‐
linked immunosorbent assays (ELISA), related immune‐assays or
mass spectrometry.3,43 Robust and reproducible EV isolation and
protein assays are still under development and until these technol-
ogies are standardized, large scale intra‐vesicular protein biomarker
validation and clinical implementation are difficult to realize. This is
different for EV membrane‐associated proteins that can be detected
with antibodies while the vesicle remains intact. Standard ELISA‐like
assays might capture and detect the EV protein of interest, directly
from biofluids.12,43
5 | CONCLUSIONS
In this study, we investigated previously‐identified EV‐derived
markers on large cohorts of patient tissue samples for validation of
diagnostic and prognostic differential expression. High expression of
cytoplasmic XPO1 shows a strong correlation with PCa progression,
while no differential tissue expression of PDCD6IP was observed.
The increase in cytoplasmic XPO1 during the progression of PCa can
explain the higher abundance in secreted EVs.
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